Q3 EPS Estimates for Revolution Medicines Reduced by Wedbush

Key Points

• Wedbush has significantly reduced its Q3 2025 EPS estimate for Revolution Medicines to ($1.33), down from a previous estimate of $0.02.
• The company's recent earnings results showed a loss of ($1.31) per share, missing analyst estimates by ($0.37), despite a slight revenue increase year-over-year.
• The consensus target price for Revolution Medicines shares is currently set at $73.67, with 14 analysts rating the stock as a buy.

Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) - Equities researchers at Wedbush reduced their Q3 2025 earnings estimates for Revolution Medicines in a research report issued on Thursday, September 11th. Wedbush analyst R. Driscoll now expects that the company will post earnings per share of ($1.33) for the quarter, down from their prior estimate of $0.02. Wedbush currently has a "Outperform" rating and a $77.00 price objective on the stock. The consensus estimate for Revolution Medicines' current full-year earnings is ($3.49) per share. Wedbush also issued estimates for Revolution Medicines' Q4 2025 earnings at ($1.36) EPS, FY2025 earnings at ($5.14) EPS, Q1 2026 earnings at ($1.40) EPS, Q2 2026 earnings at ($1.43) EPS, Q3 2026 earnings at ($1.46) EPS, Q4 2026 earnings at ($1.48) EPS, FY2026 earnings at ($5.77) EPS, FY2027 earnings at ($5.52) EPS and FY2028 earnings at ($3.67) EPS.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($1.31) EPS for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.37). During the same quarter in the previous year, the firm posted ($0.81) EPS. The business's revenue was up .0% on a year-over-year basis.

Several other brokerages have also recently issued reports on RVMD. Guggenheim restated a "buy" rating and issued a $80.00 target price on shares of Revolution Medicines in a report on Wednesday, June 25th. The Goldman Sachs Group raised their target price on shares of Revolution Medicines from $65.00 to $73.00 and gave the stock a "buy" rating in a report on Friday. Raymond James Financial initiated coverage on shares of Revolution Medicines in a report on Friday. They issued a "strong-buy" rating and a $72.00 target price on the stock. Lifesci Capital initiated coverage on shares of Revolution Medicines in a research report on Monday, August 18th. They issued an "outperform" rating and a $80.00 price target on the stock. Finally, Piper Sandler initiated coverage on shares of Revolution Medicines in a research report on Monday, August 18th. They issued an "overweight" rating and a $75.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating and fourteen have assigned a Buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $73.67.

Revolution Medicines Trading Up 0.7%

Shares of RVMD stock opened at $46.55 on Monday. Revolution Medicines has a 12-month low of $29.17 and a 12-month high of $62.40. The company has a current ratio of 11.79, a quick ratio of 11.79 and a debt-to-equity ratio of 0.13. The firm's 50 day moving average is $37.94 and its 200 day moving average is $38.17. The stock has a market capitalization of $8.70 billion, a P/E ratio of -10.34 and a beta of 1.12.

Insider Transactions at Revolution Medicines

In other Revolution Medicines news, CFO Jack Anders sold 5,238 shares of Revolution Medicines stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $40.17, for a total value of $210,410.46. Following the sale, the chief financial officer directly owned 113,314 shares in the company, valued at approximately $4,551,823.38. The trade was a 4.42% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 8.20% of the company's stock.

Hedge Funds Weigh In On Revolution Medicines

A number of institutional investors and hedge funds have recently made changes to their positions in RVMD. CWM LLC boosted its stake in shares of Revolution Medicines by 171.3% during the 2nd quarter. CWM LLC now owns 917 shares of the company's stock worth $34,000 after purchasing an additional 579 shares during the period. Banque Transatlantique SA bought a new position in Revolution Medicines in the 1st quarter worth about $42,000. Quarry LP purchased a new stake in shares of Revolution Medicines in the 1st quarter worth approximately $50,000. Twin Tree Management LP purchased a new stake in shares of Revolution Medicines in the 1st quarter worth approximately $58,000. Finally, a16z Perennial Management L.P. purchased a new stake in shares of Revolution Medicines in the 2nd quarter worth approximately $67,000. 94.34% of the stock is owned by hedge funds and other institutional investors.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.